Abstract:
Ascophyllum nodosum, a brown algae abundantly found along the North Atlantic coast, is recognized for its high polysaccharide content. In this study, we investigated the anti-hyperlipidemic effect of fucoidans derived from A. nodosum, aiming to provide information for their potential application in anti-hyperlipidemic therapies and to explore comprehensive utilization of this Iceland brown seaweed. The crude fucoidan prepared from A. nodosum was separated using a diethylethanolamine column, resulting in two fucoidan fractions, AFC-1 and AFC-2. Both fractions were predominantly composed of fucose and xylose. AFC-1 exhibited a higher sulfate content of 27.8% compared to AFC-2 with 17.0%. AFC-2 was primarily sulfated at the hydroxy group of C2, whereas AFC-1 was sulfated at both the hydroxy groups of C2 and C4. To evaluate the anti-hyperlipidemic effect, a hyperlipidemia mouse model was established by feeding mice a high-fat diet. The effects of AFC-1, AFC-2, and the crude extract were investigated, with the drug atorvastatin used as a positive comparison. Among the different fucoidan fractions and doses, the high dose of AFC-2 administration demonstrated the most significant anti-hyperlipidemic effect across various aspects, including physiological parameters, blood glucose levels, lipid profile, histological analysis, and the activities of oxidative stress-related enzymes and lipoprotein-metabolism-related enzymes (p < 0.05 for the final body weight and p < 0.01 for the rest indicators, compared with the model group), and its effect is comparable to the atorvastatin administration. Furthermore, fucoidan administration resulted in a lower degree of loss in gut flora diversity compared to atorvastatin administration. These findings highlight the significant biomedical potential of fucoidans derived from A. nodosum as a promising therapeutic solution for hypolipidemia.
摘要:
夜蛾,一种在北大西洋沿岸大量发现的褐藻,因其多糖含量高而得到认可。在这项研究中,我们研究了来自A.nodosum的岩藻依聚糖的抗高脂血症作用,旨在为其在抗高脂血症治疗中的潜在应用提供信息,并探索这种冰岛褐藻的综合利用。使用二乙基乙醇胺柱分离由A.nodosum制备的粗岩藻依聚糖,产生两个岩藻依聚糖部分,AFC-1和AFC-2。两种级分主要由岩藻糖和木糖组成。与17.0%的AFC-2相比,AFC-1表现出较高的27.8%的硫酸盐含量。AFC-2主要在C2的羟基处被硫酸化,而AFC-1在C2和C4的两个羟基处被硫酸化。为了评估抗高脂血症的作用,用高脂饮食喂养小鼠建立高脂血症小鼠模型。考察了AFC-1、AFC-2和粗提物的作用,与药物阿托伐他汀作为阳性比较。在不同的岩藻依聚糖组分和剂量中,高剂量的AFC-2给药在各个方面表现出最显著的抗高脂血症作用,包括生理参数,血糖水平,血脂谱,组织学分析,以及氧化应激相关酶和脂蛋白代谢相关酶的活性(最终体重p<0.05,其余指标p<0.01,与模型组相比),其效果与阿托伐他汀相当。此外,与阿托伐他汀给药相比,岩藻依聚糖给药导致肠道菌群多样性损失程度较低。这些发现突出了源自结节性念珠菌的岩藻依聚糖作为低脂血症的有希望的治疗解决方案的重要生物医学潜力。